Travailler chez Siemens HealthineersEspace presseInvestor Relations
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases and Conditions
  4. Sepsis & Inflammation
  5. IMMULITE 2000 XPi System Inflammation Panel

IMMULITE 2000 XPi System Inflammation Panel

Broadest cytokine menu on the market

Siemens Healthineers is the first supplier to offer fully automated, random-access immunoassays for IL-1β, IL-2R, IL-6, IL-8, IL-10, TNFα, and LBP. These assays are available on IMMULITE® 2000/2000 XPi Immunoassay System, making the study of inflammatory diseases accessible to any-sized lab and providing a fuller disease-state picture to clinicians.

Siemens Healthineers IMMULITE 2000 XPi System Inflammation Panel

Avantages

Tech wearing blue gloves loading a sample rack on the IMMULITE 2000 XPi System
  • Respond to clinical demands with a more comprehensive automated inflammation panel that provides high-quality, highly sensitive and specific, standardized assay results.
  • Reduce costs by consolidating cytokine testing on a single, cost-efficient system.
  • Improve inflammation testing workflow by leveraging an automated, easy-to-use analyzer.
Chart depicting key cytokines and their functions

Key cytokines, their function, and pathological association/effect.1,2

Early detection of inflammatory markers can indicate the onset of inflammatory disease, and accurate measurement of cytokines can help physicians assess risk and make timely interventions.

Elevated serum levels of pro- and anti-inflammatory cytokines have been found in patients with acute or chronic inflammatory diseases and conditions, such as cytokine storm,3 cancer,4 major depressive disorder,5 respiratory diseases,3 rheumatoid arthritis,6 and diabetes.7

IMMULITE 2000 XPi System Inflammation Panel

IMMULITE 2000 XPi system allows labs to begin addressing the complexity of inflammatory responses with high-quality immunoassays on a multiplexed, high-throughput system.

Achieve consistent, accurate detection of disease using highly sensitive assays with a turnaround time of just 35–65 minutes.†


Tech wearing blue gloves loading a sample rack on the IMMULITE 2000 XPi System
  • Respond to clinical demands with a more comprehensive automated inflammation panel that provides high-quality, highly sensitive and specific, standardized assay results.
  • Reduce costs by consolidating cytokine testing on a single, cost-efficient system.
  • Improve inflammation testing workflow by leveraging an automated, easy-to-use analyzer.

Assay characteristics  

IMMULITE 2000/2000 XPi Systems assay characteristics

IMMULITE 2000/2000 XPi Systems assay characteristics


AS = analytical sensitivity 
FS = functional sensitivity

Staying Ahead of the Cytokine Storm

Staying Ahead of the Cytokine Storm

Patients with a cytokine storm have been found to have high serum levels of pro- and anti-inflammatory cytokines, such as interleukin-6 (IL-6).9

This key marker is an early indicator of inflammatory response to illness. IL-6 rises within hours of substantial injury or infection and can be measured to help reveal if a patient is suffering an acute response to infection and if the response is waning slowly or rapidly, which can help to assess the patient’s current and future disease risks.10-12

Testing for key inflammation markers can help clinicians stay ahead of cytokine storm by assisting in the identification of severe inflammatory response in patients.

Approche clinique

"Cytokine tests, particularly IL-6, should be used where possible to assess severe patients suspected of hyperinflammation." — IFCC8

Webinars and Related Products

Physician standing over patient while listening to chest with stethoscope

Webinar: sIL-2R in immune-mediated diseases

Select Science | March 28, 2024

Explore the clinical value of measuring sIL-2R in different types of immunological disorders.

IMMULITE 2000 XPi Immunoassay System

IMMULITE 2000 XPi Immunoassay System

Providing multiple tests on a single, easy-to-use, and compact analyzer, the IMMULITE® 2000 XPi Immunoassay System makes it simple to scale your capabilities without disrupting regular day-to-day operations.

Téléchargements

1
Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019;20(23):6008. Available from: https://doi.org/10.3390/ijms20236008
2
Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Ann Rev Immunol. 2018;36(1):411-33. Available from: https://doi.org/10.1146/annurev-immunol-042617-053352 
3
Pacheco-Hernández LM, Ramírez-Noyola JA, Gómez-García IA, Ignacio-Cortés S, Zúñiga J, Choreño-Parra JA. Comparing the cytokine storms of COVID-19 and pandemic influenza. J Interferon Cytokine Res. 2022;42(8):369-92. Available from: https://doi.org/10.1089/jir.2022.0029
4
Xia W, Chen W, Zhang Z, Wu D, Wu P, Chen Z, Li C, Huang J. Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis. PLoS ONE. 2015;10(4). Available from: https://doi.org/10.1371/journal.pone.0123484
5
Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 2015;25(10):1532-43. Available from: https://doi.org/10.1016/j.euroneuro.2015.06.007
6
Lin Y-J, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880. Available from: https://doi.org/10.3390/cells9040880
7
Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev.2020;16(5):442-9. Available from: https://doi.org/10.2174/1573399815666191024085838
8
https://ifcc.org/resources-downloads/ifcc-information-guide-on-covid-19-introduction/5-biochemical-monitoring-of-covid-19-patients/ (accessed 2024 Feb 19)
9
Fajgenbaum DC, June CH. Cytokine storm. NEJM. 2020;383(23):2255-73. Available from: https://doi.org/10.1056/NEJMra2026131
10
Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis. Arch Intern Med. 2007;167(15):1655-63.
11
Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care. 2004;8(2):R82.
12
Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, et al. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock. 2005;23(6):488-93.
*
Research use only in the U.S.
†
Source: Siemens Healthineers IFUs.
Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability. IMMULITE and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners
Contacts